Christian Siebert

1
Christian Siebert

• Competitiveness in Pharmaceuticals and
  Biotechnology, DG Enterprise Industry,
  European Commission.

2
The Pharmaceutical Forum Supporting innovation
3
European Commission
Enterprise and Industry Directorate-General
Conference Financing Sustainable Healthcare in
Europe New approaches for better outcomes,
Helsinki, 7-8 Feb. 2007
Pharmaceutical Forum
Presenter Christian Siebert Head of
Unit Competitiveness in the Pharmaceuticals
Industry and Biotechnology Enterprise and
Industry DG
4
European Commission
Enterprise and Industry Directorate-General

• Challenges and Opportunities for health systems
  in EU
• Aging population
• Health inequalities
• Financial pressures on health budgets
• Need to create headway for innovation
• Strengthen science industry competitiveness
• Health as contribution to quality of life, growth
  and employment

5
What was G10?
Round-table with 11 high level representatives
from Member States, industry, patients health
funds. To produce recommendations on ways to
encourage innovation and competitiveness in line
with public health objectives
6
How will we take them forward?

• Principles
• Broad participation
• Highest level political participation technical
  preparation
• Process facilitated by Commission

7
Information to Patients

• Need to improve information to
• Patients, but how?
• Legislation on information drafted before the
  Internet
• No clear distinction between information
  advertising
• Factors to consider
• Uneven information provision across the Union
• Potential role of industry
• Growing demands from patients for better info

• Working Group on Patient Information
• Examine options to
• Improve access to information
• Provide tools to access quality
• Put medicine information into a broader context
• Provide best practice
• Develop a partnership
• Build on existing expertise and take account of
  existing initiatives
• EuroPharm Database
• EU Health Portal

8
Pricing Reimbursement

• Multiple expectations and
• regulations
• Need to balance two expectations on pricing
• MS duty to keep healthcare affordable
• Industrys need for a return on investment
• National competence
• Decision-process needs to be in line with
  Transparency Directive

• Working Group on Pricing Reimbursement
• Share and examine experiences with different PR
  mechanisms and cost-containment strategies on
• Impact on cost
• Access to market
• Reward for innovation
• Unequal access and affordability over Europe
• Consider impact of cross-national mechanisms
  (e.g. international reference pricing)
• Aim for greater certainty to allow to improve
  climate for investment

9
Relative Effectiveness

• New, complex, though
• promising area
• Aims to target limited public funds towards most
  valuable medicines
• Requires in-depth scientific and clinical
  assessment
• Available information is usually fragmented
• Absence of standard procedures often leads to
  duplication across the EU

• Working Group on Relative Effectiveness
• Examine how to share experiences and build common
  approaches
• Focus on
• Improving quality of data
• Establishing some consensus on data requirements
• Establishing best practice
• Take account of existing initiatives
• E.g. MEDEV, Baltics, HTA-network etc.

10
Forum 29/9/06 Progress Report ()

• Targets
• Patient information quality principles and model
  info package diabetes
• Pricing toolbox of policies and impact on
  access, innovation and cost
• Relative Effectiveness shared methodology data
  collection and assessment

() http//ec.europa.eu/health/ph_overview/other_p
olicies/pharmaceutical/pharma_forum_progres_report
092006_en.pdf